NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women


Peritoneal Carcinomatosis Index (PCI);
cytoreductive surgery (CRS);
SMART System;
Peritoneal Metastasis;
Progression Free Survival

Recruitment Keyword(s)



Gynecologic Cancer;
Gynecologic Neoplasms;
Peritoneal Carcinomatosis;
Peritoneal Neoplasms;
Ovarian Cancer;
Ovarian Neoplasms;
Colorectal Cancer;
Colorectal Neoplasms;
appendiceal cancer;
appendiceal neoplasms

Investigational Drug(s)


Investigational Device(s)



Drug: Paclitaxel
Drug: Nilotinib

Supporting Site

National Cancer Institute


Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor. Researchers want to test a new treatment.


To learn if the combination of oral nilotinib plus paclitaxel given by IV and directly into the abdomen can reduce tumors enough for people to have surgery.


Adults aged 18 and older with peritoneal carcinomatosis that is too widespread for surgery.


Participants will be screened with:

Physical exam

Medical history

Blood and urine tests


Laparoscopy. They will get general anesthesia. Small cuts will be made in their abdomen. Tissue and fluid samples will be taken.

Surveys about their health

CT scans of their torso

Participants will have up to 4 more laparoscopies. During the first procedure, a port will be placed under the skin of their abdomen (an IP port). It will be attached to a catheter that is placed in their abdomen.

Participants will get treatment in 3-week cycles, for 3 or 6 cycles. They will take nilotinib by mouth twice daily. They will get paclitaxel by IP port (once per cycle) and by IV (twice per cycle). After cycles 3 and 6, they will have a laparoscopy and CT scans. Then they may take nilotinib and get IV paclitaxel for up to 1 year.

At study visits, participants will repeat some screening tests.

About 6 weeks after treatment ends and then every 3 months for 3 years, participants will have follow-up visits at NIH or with their local doctor.

--Back to Top--



In order to be eligible to participate in this study, an individual must meet all of the following criteria.

-Histological confirmation of peritoneal carcinomatosis from colorectal, appendiceal, small bowel, gastric, cholangiocarcinoma, breast, ovarian, or other gynecologic (i.e., endometrial, fallopian tube, primary peritoneal, cervical) primary by the Laboratory of Pathology, NCI.

-Participants must have been treated with at least one line of approved systemic chemotherapy, with demonstrated resistance or lack of response

-Measurable or evaluable disease as defined by RECIST v1.1. criteria and/or by Peritoneal Carcinomatosis Index (PCI)

-Participants must be assessed to not be candidates for cytoreductive surgery, with laparoscopically assessed PCI score thresholds as indicated below:

--Primary Histology PCI Cutoff for Eligibility

---Gastric Total Score >= 10 (out of 39 possible points)

---Others Total Score >= 20 (out of 39 possible points)

---Any Jejunoileal Score >= 4 (out of 12 possible points)

-Age >= 18 years

-ECOG performance status <= 2 (Karnofsky >= 60%).

-Participants must have adequate organ and marrow function as defined below:

--Absolute neutrophil count >= 1,000/mcL

--Platelets >= 100,000/mcL

--Total bilirubin within <= 1.5x institutional upper limit of normal (ULN)

--AST (SGOT)/ ALT (SGPT) <= 3x institutional ULN, or <= 5.0x ULN in participants with liver metastases (only)

--Serum potassium and magnesium greater than institutional lower limit of normal

--Creatinine <= 1.5 mg/dL or creatinine clearance >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal calculated using eGFR

-Breastfeeding participant must agree to discontinue breastfeeding.

-Females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 90 days after last study treatment. Should a female suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.

-Ability of participant to understand and the willingness to sign a written informed consent document.

-Participants must agree to co-enrollment on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors


An individual who meets any of the following criteria will be excluded from participation in this study.

-Participants who are receiving any other investigational agents or who have received an investigational agent within 30 days prior to the start of study treatment.

-Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs.

-Participants who have received systemic (i.e., oral or intravenous) chemotherapy or other anti-cancer therapy (i.e., immunotherapy) within either 5 half-lives or within 30 days of the last dose of individual agent(s) administered prior to the start of study treatment, whichever is shorter.

-Participants who have undergone major abdominal surgery within the last 12 weeks prior to the start of study treatment.

Note: Exclusion of participants who have undergone major abdominal surgery within the last 12 weeks prior to start of study treatment is to allow for scar tissue formation from that surgery to stabilize. Participant ECOG performance status will be checked to account for prolonged or difficult recoveries from other types of major surgery that would appropriately influence eligibility assessment.

-Participants who have received previous intraperitoneal chemotherapy within the last 6 months prior to the start of study treatment

-Participants requiring the use of drugs known to prolong the QT interval or known to strongly inhibit CYP3A4, 2C8. Participants on such agents at the time of screening are permitted on study if an alternative that does not have the same pharmacokinetic interactions can be found.

-Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Note: No subject will be excluded based on a social situation prior to consultation with the Department of Social Work.

-Pregnant women are excluded from this study.

-Participants with HIV who have detectable viral load, or whose ART contains QTc Prolonging Medications or CYP3A4 Inhibitors regardless of viral load. (NOTE: Participants with HIV who have an undetectable viral load and have been on stable doses of ART that does not prolong the QT interval or is a strong CYP3A4, 2C8 inhibitor are eligible).

-QTcF interval of >= 450 msec at study entry, or congenital long QT syndrome.

-More than 3 liters of ascites present at initial laparoscopy, or history of more than two therapeutic paracentesis procedures, each yielding at least 1.5 liters of fluid, in the 30 days prior to initial laparoscopy, or confirmation of predominantly mucinous ascites at

the time of screening laparoscopy.

-Advanced hepatic failure, as indicated by Child-Pugh Class C cirrhosis.

-Sensory/motor neuropathy >= Grade 2

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Andrew M. Blakely, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 4-3760B
(240) 760-7647

Audra A. Satterwhite, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4W5920
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3552

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--